Home
Search

Letters, Testimony & Comments

BIO submits letters, testimony, and comments to government and regulatory bodies throughout the United States and around the world.

Featured Letters, Testimony, & Comments
BIO Statement to the U.S. International Trade…
Learn more
Ag Value Chain Letter to President Biden on…
As organizations representing America’s highly innovative and competitive food and agricultural value chain, we write to express our thanks for USTR’s announcement that it will begin technical consultations with Mexico concerning its action to ban…
Learn more
BIO Comments to CMS on the Proposed Rule Dealing…
BIO’s comments on specific aspects of CMS’s Proposed Rule on Medicaid drug pricing are presented below.
Learn more
All Letters, Testimony & Comments
  • Show All
Search
BIO Statement to the U.S. International Trade Commission (USITC) for its Investigation into the TRIPS
March 17, 2023
Ag Value Chain Letter to President Biden on Technical Consultations with Mexico on Corn
March 9, 2023
As organizations representing America’s highly innovative and competitive food and agricultural value chain, we write to express our thanks for USTR’s announcement that it will begin technical consultations with Mexico concerning its action to ban…
BIO Comments to CMS on the Proposed Rule Dealing with Medicare Drug Pricing
February 13, 2023
BIO’s comments on specific aspects of CMS’s Proposed Rule on Medicaid drug pricing are presented below.
Ag Biotech Alliance Response to Biotech RFI
February 5, 2023
ABA has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
BIO Response to Biotech RFI
February 5, 2023
BIO has submitted comments to the Office of Science & Technology Policy on how regulations underpinning the Coordinated Framework for the Regulation of Biotechnology can better facilitate the use of biotechnology to stimulate the economy…
BIO comments to USTR on the Agency’s 2023 Special 301 Review, January 30, 2023
January 31, 2023
BIO Response to RFI: National Biotechnology & Biomanufacturing Initiative
January 23, 2023
BIO's response to the Office of Science & Technology Policy's Request for Information concerning the National Biotechnology & Biomanufacturing Initiative
BIO Submits Comments on FDA Guidance: Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials
January 3, 2023
On Tuesday, January 3rd, BIO submitted comments in response to the Food and Drug Administration’s (FDA) recent draft guidance containing recommendations for sponsors on monitoring growth and evaluating pubertal development in clinical trials which…
BIO Comments on FDA Discussion Paper: Distributed Manufacturing and Point-of-Care Manufacturing of Drugs
December 13, 2022
On Tuesday, December 13th, BIO submitted comments in response to a recent FDA discussion paper for stakeholders on distributed manufacturing (DM) and point-of-care (POC) manufacturing. In the comments submitted, BIO commended the FDA on its…
BIO/Stakeholder letter to the Senate Judiciary Committee in opposition to the “Pride in Patent Ownership Act” (S. 2774)
December 9, 2022